^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    onvansertib (PCM-075)

    i
    Company:
    Cardiff Oncology, Nerviano Medical Sciences
    Drug class:
    PLK1 inhibitor
    Related drugs:
    Apply
    Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/01/2019
    Primary completion :
    06/01/2026
    Completion :
    02/01/2028
    UGT1A1 • CD4
    |
    UGT1A1*1*1
    |
    Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)
    Onvansertib + Paclitaxel In TNBC (NCT05383196)
    Phase 1/2
    Antonio Giordano, MD
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    09/30/2022
    Primary completion :
    02/15/2026
    Completion :
    02/15/2029
    HER-2
    |
    HER-2 negative
    |
    paclitaxel • onvansertib (PCM-075)
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation (NCT06106308)
    Phase 2
    Cardiff Oncology
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    02/27/2024
    Primary completion :
    11/01/2026
    Completion :
    01/01/2027
    KRAS • NRAS
    |
    KRAS mutation • NRAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation (NCT03829410)
    Phase 1/2
    Cardiff Oncology
    Completed
    Last update posted :
    03/01/2024
    Initiation :
    05/06/2019
    Primary completion :
    01/29/2024
    Completion :
    01/29/2024
    KRAS • BRAF
    |
    KRAS mutation • BRAF mutation • KRAS exon 2 mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer (NCT04446793)
    Phase N/A
    Cardiff Oncology
    No Longer Available
    Last update posted :
    02/12/2024
    KRAS
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation (ONSEMBLE) (NCT05593328)
    Phase 2
    Cardiff Oncology
    Active, not recruiting
    Last update posted :
    01/17/2024
    Initiation :
    03/17/2023
    Primary completion :
    11/01/2025
    Completion :
    04/01/2026
    KRAS • NRAS
    |
    NRAS mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • onvansertib (PCM-075)